سعر ريليكاست 5مجم 10 اقراص 2022

Montelukast 5 mg chewable tablets, a selective cysteinyl leukotriene (CysLT1) receptor antagonist used in asthma and allergic rhinitis.

• Prophylaxis and chronic treatment of asthma (5 mg chewable tablet for patients 6 to 14 years).Population: Children 6-14 yearsDailyMed (NLM)
• Prevention of exercise-induced bronchoconstriction (single dose at least 2 hours before exercise).Population: Children 6-14 yearsDailyMed (NLM)
• Relief of symptoms of seasonal and perennial allergic rhinitis, reserved for inadequate response or intolerance to alternative therapies.Population: Children 6-14 yearsDailyMed (NLM)

• Most common (>=5%): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhoea, otitis media, influenza, rhinorrhoea, sinusitis, otitis; postmarketing neuropsychiatric events, hypersensitivity, hepatic injury.International label, same formulation · DailyMed (NLM)

• Hypersensitivity to any component.International label, same formulation · DailyMed (NLM)

• Boxed warning: serious neuropsychiatric events (agitation, aggression, depression, sleep disturbance, suicidal thoughts and behaviour); discuss risks, monitor, and discontinue immediately if symptoms occur.International label, same formulation · DailyMed (NLM)
• Not for acute asthma attacks; do not abruptly substitute for inhaled or oral corticosteroids; aspirin-sensitive patients should continue to avoid aspirin/NSAIDs.International label, same formulation · DailyMed (NLM)
• Systemic eosinophilia/Churg-Strauss-type vasculitis reported, sometimes with oral corticosteroid reduction.International label, same formulation · DailyMed (NLM)

• Phenobarbital and other potent CYP inducers (e.g. rifampin)Phenobarbital decreased montelukast AUC by about 40%; no dose adjustment, but clinical monitoring is reasonable.DailyMed (NLM)
• GemfibrozilIncreased montelukast exposure 4.4-fold; no dosage adjustment required per label.DailyMed (NLM)

• Published cohort data have not established a drug-associated risk of major birth defects; poorly controlled asthma in pregnancy carries maternal and fetal risks.International label, same formulation · DailyMed (NLM)
• Montelukast is present in human milk; available data do not suggest a significant risk to the breastfed infant.International label, same formulation · DailyMed (NLM)

• Montelukast: Binds with high affinity and selectivity to the CysLT1 receptor, inhibiting the actions of LTD4 without agonist activity.